Clinical Trials Logo

Nalbuphine clinical trials

View clinical trials related to Nalbuphine.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04020016 Active, not recruiting - Hepatic Impairment Clinical Trials

Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch

Start date: October 24, 2018
Phase: Phase 1
Study type: Interventional

This research study will evaluate the effect of liver disease on the pharmacokinetics (the breakdown of the drug in the body) of parallel-group, multiple oral doses nalbuphine extended release (NAL ER), tablets in people with liver disease (mild, moderate and severe), compared to people with normal liver function. The study will also test the safety and tolerability of the NAL ER, when it is given to subjects with mild, moderate and severe liver disease, compared to subjects with normal liver function. This protocol will also study the effects of this drug on itching in liver disease subjects if they report some itching prior to taking part in this study.